Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.

Li H, Han TH, Hunder NN, Jang G, Zhao B.

J Clin Pharmacol. 2017 Sep;57(9):1148-1158. doi: 10.1002/jcph.920. Epub 2017 May 17.

2.

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.

Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, Stiff P, Viviani S, Sweetenham JW, Radford J, Zhu Y, Bonthapally V, Thomas E, Richhariya A, Hunder NN, Walewski J, Moskowitz CH.

Br J Haematol. 2016 Dec;175(5):860-867. doi: 10.1111/bjh.14316. Epub 2016 Sep 21.

3.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group.

Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19. Erratum in: Lancet. 2015 Aug 8;386(9993):532. Lancet. 2015 Aug 8;386(9993):532.

PMID:
25796459
4.

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM.

Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.

PMID:
24239220
5.

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.

Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A.

Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.

6.

Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.

Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, Kamel-Reid S, Tron V, Chen BE, Hunder NN, Hagerman L, Walsh W, Eisenhauer EA.

J Clin Oncol. 2012 Sep 20;30(27):3396-401. doi: 10.1200/JCO.2011.40.0655. Epub 2012 Aug 20.

PMID:
22915661
7.

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.

Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E.

Hepatology. 2010 Sep;52(3):822-32. doi: 10.1002/hep.23743.

PMID:
20564352
8.

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C.

N Engl J Med. 2008 Jun 19;358(25):2698-703. doi: 10.1056/NEJMoa0800251.

9.

Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.

Groh V, Li YQ, Cioca D, Hunder NN, Wang W, Riddell SR, Yee C, Spies T.

Proc Natl Acad Sci U S A. 2005 May 3;102(18):6461-6. Epub 2005 Apr 11.

10.

Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis.

Martinez-Taboada V, Hunder NN, Hunder GG, Weyand CM, Goronzy JJ.

J Mol Med (Berl). 1996 Nov;74(11):695-703.

PMID:
8956156
11.

HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis.

Weyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ.

Arthritis Rheum. 1994 Apr;37(4):514-20.

PMID:
8147928
12.

Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes.

Weyand CM, Schönberger J, Oppitz U, Hunder NN, Hicok KC, Goronzy JJ.

J Exp Med. 1994 Mar 1;179(3):951-60.

Supplemental Content

Loading ...
Support Center